Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation by Lamberti, María Julia et al.
ORIGINAL RESEARCH
published: 08 November 2019
doi: 10.3389/fimmu.2019.02614
Frontiers in Immunology | www.frontiersin.org 1 November 2019 | Volume 10 | Article 2614
Edited by:
Jessica Dal Col,
University of Salerno, Italy
Reviewed by:
Elisa Panzarini,
University of Salento, Italy
Evelien Smits,
University of Antwerp, Belgium
*Correspondence:





This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology
Received: 14 July 2019
Accepted: 21 October 2019
Published: 08 November 2019
Citation:
Lamberti MJ, Mentucci FM, Roselli E,
Araya P, Rivarola VA, Rumie Vittar NB
and Maccioni M (2019) Photodynamic
Modulation of Type 1 Interferon
Pathway on Melanoma Cells
Promotes Dendritic Cell Activation.
Front. Immunol. 10:2614.
doi: 10.3389/fimmu.2019.02614
Photodynamic Modulation of Type 1
Interferon Pathway on Melanoma
Cells Promotes Dendritic Cell
Activation
María Julia Lamberti 1, Fátima María Mentucci 1, Emiliano Roselli 2, Paula Araya 2,
Viviana Alicia Rivarola 1, Natalia Belén Rumie Vittar 1* and Mariana Maccioni 2*
1Departamento de Biología Molecular, Facultad de Ciencias Exactas, Físico-Químicas y Naturales, Instituto de Biotecnología
Ambiental y Salud, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad Nacional de Río Cuarto,
Córdoba, Argentina, 2Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Centro de Investigaciones en
Bioquímica Clínica e Inmunología, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad Nacional de
Córdoba, Córdoba, Argentina
The immune response against cancer generated by type-I-interferons (IFN-1) has
recently been described. Exogenous and endogenous IFN-α/β have an important role
in immune surveillance and control of tumor development. In addition, IFN-1s have
recently emerged as novel DAMPs for the consecutive events connecting innate and
adaptive immunity, and they also have been postulated as an essential requirement
for induction of immunogenic cell death (ICD). In this context, photodynamic therapy
(PDT) has been previously linked to the ICD. PDT consists in the administration of a
photosensitizer (PS) and its activation by irradiation of the affected area with visible
light producing excitation of the PS. This leads to the local generation of harmful
reactive oxygen species (ROS) with limited or no systemic defects. In the current work,
Me-ALA inducing PpIX (endogenous PS) was administrated to B16-OVA melanoma
cells. PpIX preferentially localized in the endoplasmic reticulum (ER). Subsequent PpIX
activation with visible light significantly induced oxidative ER-stress mediated-apoptotic
cell death. Under these conditions, the present study was the first to report the in vitro
upregulation of IFN-1 expression in response to photodynamic treatment in melanoma.
This IFN-α/β transcripts upregulation was concurrent with IRF-3 phosphorylation at
levels that efficiently activated STAT1 and increased ligand receptor (cGAS) and ISG
(CXCL10, MX1, ISG15) expression. The IFN-1 pathway has been identified as a critical
molecular pathway for the antitumor host immune response, more specifically for the
dendritic cells (DCs) functions. In this sense, PDT-treated melanoma cells induced
IFN-1-dependent phenotypic maturation of monocyte-derived dendritic cells (DCs)
by enhancing co-stimulatory signals (CD80, MHC-II) and tumor-directed chemotaxis.
Collectively, our findings showed a new effect of PDT-treated cancer cells by modulating
the IFN-1 pathway and its impact on the activation of DCs, emphasizing the potential
relevance of PDT in adoptive immunotherapy protocols.
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INTRODUCTION
Cutaneous melanoma is the neoplasm originated from the
melanocytes of the epidermis, and, although it corresponds
to only 4% of skin related cancers, it is the causal agent
for 80% of deaths from dermatological cancer (1). Unlike
other tumor types, melanoma incidence and its mortality rate
increased each year, an event associated with excesses in sun
exposure and the progressive loss of the ozone layer (2).
When surgical excision is performed on tumors with early
diagnosis, the average survival rate at 10 years is 80%. However,
in the case of metastatic melanoma, survival decreases to
<10% (3). Therefore, the major challenge focuses on designing
new therapies to treat melanoma in advanced stages with
systemic dispersion. In this sense, immunotherapy emerges as a
promising therapeutic option that involves therapeutic strategies
with the common aim of enhancing the strengthens of the
patient’s immune system to advance upon tumors (4, 5). These
systemic treatments for melanoma, approved or in experimental
phase, include the administration of cytokines and other non-
specific immunostimulatory molecules (IL-2, IFN-α2), active
immunization (vaccination) with tumor cells, dendritic cells
(DCs) or other molecules (recombinant antigens), adoptive
transfer of T lymphocytes and monoclonal antibodies against
immune checkpoint inhibitors (anti-CTLA-4, anti-PD1, anti-
PDL1) (6).
Type I interferons are pleiotropic polypeptides classified
according to the activity, structure and type of receptor to which
they are bound in IFN-α, β, κ, ω, τ , and ε. Among them, IFN-α
and IFN-β are the best characterized in terms of the stimulation
of innate and adaptive immunity induced through autocrine and
paracrine binding to the common IFNAR1/2 receptor. Previous
reports indicated that type I IFNs (IFN-1) have an essential
role in both basal and therapeutic-induced immune responses to
cancer (7).
Clinical studies showed that high-dose IFN-α2 treatment
was favorable for prolonging patient survival, therefore the
exogenous administration of this was authorized as an adjuvant
treatment for melanoma in 1996 (8). Unfortunately, high-dose
treatment is also linked with adverse effects that can be reduced
with lower doses, but they do not offer the same therapeutic good
outcome (9). On the other hand, IFN-β treatment demonstrated
limited efficacy and high toxicity for the treatment of metastatic
melanoma (10, 11).
Studies about treatment of melanoma with recombinant type
I IFN are ongoing and aim to develop more efficient methods
of administration, design optimal treatment regimens, and
identify the patient populations that are most likely to benefit.
Nonetheless, given their antitumor immune-promoting activity,
a variety of stimuli that induce the endogenous expression
of IFN-1 are currently evaluated as promising adjuvants in
vaccines. In fact, contrasting with the traditional adjuvants like
aluminum compounds, which mainly promote humoral immune
responses, IFN-α/β is a very effective tool to enhance cell-
mediated immunity (12). Therefore, complementary efforts have
focused on developing and identifying novel stimuli capable of
promoting the IFN-1 pathway.
In this context, the molecular mechanisms subjacent the
promotion of an immunogenic modality of cell death, that
is, immunogenic cell death (ICD) have been elucidated. ICD
includes spatiotemporally coordinated changes in the cell
surface and the secretion of soluble mediators. Such signals
are recognized by innate receptors expressed by dendritic
cells to stimulate the antigenic presentation to T cells. These
exposure/released danger signals, called damage-associated
molecular patterns (DAMPs), include, but are not limited to,
several innate immune stimulators, such as surface-exposed “eat
me” signals (e.g., calreticulin, CRT), “find me” signals (e.g.,
ATP) and other factors (e.g., HMGB1) (13–15). Recently, IFN-
1 signaling has been postulated as an essential requirement for
ICD (16).
In the last decade, several investigations have analyzed the
ability of conventional antitumor to promote ICD, in order to
optimize their clinical use and to rationalize their application
instead of more immunosuppressive drugs (17). In this context,
photodynamic therapy (PDT) has been previously linked to the
ICD. PDT is a well-known two-stage procedure. First, non-toxic
photosensitizer drug (PS) is administrated and accumulates in
tumor sites. After administration of the photosensitizer agent
(PS), tumor loci are irradiated with a PS-exciting light of
specific wavelength. None of these are independently toxic, but
together produce a photochemical reaction, turning molecular
oxygen into reactive oxygen species (ROS), which act directly
on tumor cells or indirectly by damaging tumor-associated
vasculature (18–22).
PDT has been associated with some of the main DAMPs
involved in immunogenic cell death (23), such as CRT (24, 25),
ATP (26), and HMGB1 (24). However, the relevance of PDT-
mediated tumor cell death and its relationship with the IFN-1
pathway remain to be determined.
In the current study, we demonstrated that photodynamic
treatment of melanoma cells in vitro resulted in IFN-
α/β upregulation. Correspondingly, DCs co-cultured
with PDT-treated tumor cells showed a potent IFN-1-
dependent phenotypic and functional maturation. Taken
together, these results delineate a novel photomodulated
mechanism with potential application to prepare vaccines
using ex vivo stimulated DC cultures with photosensitized




LPS from Escherichia coli 055:B5, Methyl-aminolevulinic
acid (Me-ALA), Doxorubicin, N-acetyl-L-cysteine (NAC), and
BAPTA-AM were from Sigma Aldrich. The plasmid pEYFP-
Mito (mitochondrial marker) (27) was from Clontech. The
plasmid pEYFP-C1-KDEL-GFP (28) (endoplasmic reticulum
marker) was kindly provided by Dr. Sergio Grinstein (University
of Toronto, Canada). The plasmid pCRT-EGFP (29) (Green
fluorescent protein-tagged calreticulin) was kindly provided by
Dra. Marta Hallak (CIQUIBIC, Argentina).
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Cell Culture
B16-OVA murine melanoma cells were grown, as previously
described, “in complete medium DMEM (Dulbecco’s modified
Eagle medium high glucose 1X, Gibco) supplemented with
10% v/v fetal bovine serum (FBS) (PAA Laboratories), 1%
v/v glutamine (GlutaMAXTM 100X Gibco), 1% v/v antibiotic
(Penicillin 10,000 units/mL–streptomycin 10,000µg/mL Gibco)
and 1% v/v of sodium pyruvate 100mM (Gibco). Cells were
maintained in 5% CO2 and 95% air at 37◦C in a humidified
incubator. Stock cultures were stored in liquid nitrogen and used
for experimentation within 5–7 passages” (30).
Animals
C57BL/6 were purchased from Universidad Nacional de La
Plata (Buenos Aires, Argentina) and IFNAR1−/− were kindly
provided by CIBICI-UNC (Cordoba, Argentina, purchased from
Jackson Laboratory) (31). Animals were maintained under
specific pathogen-free conditions at the Animal Resource Facility
of Facultad de Ciencias Exactas, Físico-Químicas y Naturales
(Universidad Nacional de Río Cuarto) in accordance with the
experimental ethics committee guidelines. Experiments were in
compliance with the Guide for the Care and Use of Laboratory
Animals published by the NIH and approved by the Comité de
Ética de la Investigación (COEDI) from Universidad Nacional de
Río Cuarto.
Photodynamic Treatment
As previously described, B16-OVA cells monolayers “were
washed twice with PBS to remove all traces of FBS and then
incubated with 5-methylaminolevulinic acid (Me-ALA, Sigma)
in medium without FBS for 4 h to allow the endogenous
generation of the photosensitizer PpIX. After Me-ALA
incubation, tumor cells were irradiated at room temperature with
monochromatic light source (636 ± 17 nm) using a MultiLED
system (coherent light). The fluence rate was 0.89 mW/cm2, as
measured by Radiometer Laser Mate-Q. Drug solution was then
removed and replaced with fresh medium” (30).
Photosensitizer Localization Assay
B16-OVA cells were seeded on glass coverslips in a 24-well plate
and allowed to attach overnight. Next, cells were transfected
with pEYFP-Mito (mitochondrial marker) (27) or pEYFP-C1-
KDEL-GFP (endoplasmic reticulum marker) (28). Transient
transfections were performed using FuGENE R©HDTransfection
Reagent (Roche) according to the manufacturer’s instructions
(32). The following day, cells were washed twice with PBS
to remove all traces of FBS and then incubated with 5-
methylaminolevulinic acid (1mM) in medium without FBS for
4 h to allow the endogenous generation of the photosensitizer
PpIX. Next, they were fixed with paraformaldehyde (PAF) 4%
for 20min, and the cell nuclei were stained with Hoechst (HÖ)
for visualization. The fluorescence of PpIX (red), organelles
(green) and nuclei (blue) was observed by confocal microscopy
(Olympus FV1000 Spectral confocal microscope, CIQUIBIC-
UNC-CONICET). The co-localization is evidenced in yellow
color. The analysis of the images was carried out using the free
ImageJ 1.42q software (plugging Coloc 2), and the correlation
was quantified through the Pearson coefficient (r).
Calreticulin (CRT) Localization Assay
B16-OVA cells were seeded in a 24-well plate and allowed
to attach overnight. Next, cells were transfected with pCRT-
EGFP (29) (Green fluorescent protein-tagged calreticulin).
Transient transfections were performed using FuGENE R© HD
Transfection Reagent (Roche) according to the manufacturer’s
instructions (32). The following day, cells were washed twice
with PBS to remove all traces of FBS and then incubated
with 5-methylaminolevulinic acid (0.3mM) in medium
without FBS for 4 h to allow the endogenous generation of
the photosensitizer PpIX. After Me-ALA incubation, tumor
cells were irradiated with a light dose of 0.5 J/cm2. The
localization of CRT was observed 1 h after treatment on an
inverted Carl Zeiss fluorescence microscope (UNRC) coupled
to a high resolution monochromatic digital camera. The
analysis of the images was carried out using the free ImageJ
1.42q software.
Cell Viability Assay
As previously described, “cell viability was evaluated by 1-
(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) assay,
which is reduced by mitochondrial dehydrogenases of viable cells
to non-water-soluble violet formazan crystals. Twenty-four hours
post-PDT, MTT solution (5 mg/ml in phosphate buffer saline,
PBS) was added for 3 h (dilution rate: 1/10). Then, dimethyl
sulfoxide (DMSO) was added to lyse the cells and solubilize the
precipitated formazan product. Optical density of the resulting
solution of formazan salt was read at 540 nm using ELISA reader
plate (Thermo Scientific, Multiskan FC) (33).
Analysis of Apoptosis Rate by Annexin
V-FITC/PI Assay
Twenty-four hours after treatment, the percentage of apoptotic
cells was assessed using a standard flow cytometry Annexin-
V-FITC binding assay (BD Pharmingen). Briefly, cells were
disaggregated by trypsin digestion and washed with PBS. The
pellet was incubated at room temperature with 5µg/ml Annexin
V-FITC, 5µg/ml propidium iodide (PI) and binding buffer
for 15min in the dark. Annexin V and PI fluorescence were
measured using a Millipore Guava Easycyte 6 2L cytometer.
According to the manufacturer’s instructions, “cells that stain
positive for FITC Annexin V and negative for PI are undergoing
apoptosis. Cells that stain positive for both FITC Annexin V
and PI are either in the end stage of apoptosis, are undergoing
necrosis, or are already dead. Cells that stain negative for
both FITC Annexin V and PI are alive and not undergoing
measurable apoptosis.” Data was analyzed using FlowJo
10.0.7 software.
Quantitative Real Time RT-PCR
Total RNA was extracted using Trizol Reagent (Life
Technologies) and M-MLV reverse transcriptase was used
to generate cDNA (Promega). Target transcripts were quantified
by real time qRT-PCR (Stratagene Mx3000PRO) using the
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Mx3000P software (34). Experiments were performed using
SYBR Green PCR Master Mix (Applied Biosystems) (35). The
gene-specific primers were designed with the Primer BLAST
software: GAPDH: Forward: TGCACCACCAACTGCTT
AG–Reverse: GGATGCAGGGATGATGTTC; IFN-α: Forward:
TCTGATGCAGCAGGTGGG–Reverse: AGGGCTCTCCAGA
CTTCTGCTCTG; IFN-β: Forward: GCACTGGGTGGAATGA
GACT–Reverse: AGTGGAGAGCAGTTGAGGACA; RIG1:
Forward: AAGAGCCAGAGTGTCAGAATCT–Reverse: AGCT
CCAGTTGGTAATTTCTTGG; TLR3: Forward: GTGAGATAC
AACGTAGCTGAACT–Reverse: TCCTGCATCCAAGATAGCA
AGT; MDA5: Forward: AGATCAACACCTGTGGTAACACC–
Reverse: CTCTAGGGCCTCCACGAACA; cGAS: Forward:
GAGGCGCGGAAAGTCGTAA–Reverse: TTGTCCGGTTC
CTTCCTGGA; ISG15: Forward: GGTGTCCGTGACTAACT
CCAT–Reverse: TGGAAAGGGTAAGACCGTCCT; CXCL10:
Forward: AGTGCTGCCGTCATTTTCTG–Reverse: ATTC
TCACTGGCCCGTCAT; MX1: Forward: AGACTTGCTCT
TTCTGAAAAGCC–Reverse: GACCATAGGGGTCTTG
ACCAA. Specificity was verified by melting curve analysis.
Fold change in gene expression was calculated according to the
2−11Ct method. Each sample was analyzed in triplicate. No
amplification was observed in PCR reactions containing water.
Western Blot
As previously described, “total cell lysates were extracted
with lysis buffer containing 20mM HEPES pH 7.5; 1.5mM
KCl; 1mM EDTA; 1mM EGTA; 0.15% Triton-X100; 1mM
PMSF; 1mM DTT; and a cocktail of protease inhibitors
(Sigma). The protein content of the lysate was measured
using BCA protein assay reagent (Pierce). Aliquots containing
an equal amount of protein (30 µg) were separated by
SDS-PAGE and then transferred onto PVDF membranes
(Sigma). Blots were blocked with 5% non-fat dry milk in
PBS Tween 0.1% (PBST) and then incubated with primary
antibodies overnight” (30): anti-phosphoIRF3 antibody (Cell
Signaling−4947), anti-phospo-STAT1 (Cell Signaling−9167),
anti-STAT1 (Cell Signaling−9172), anti-α-Tubulin (Cell
Signaling−2144). Next, blots were incubated with corresponding
horseradish peroxidase–conjugated IgG secondary antibody
(anti-rabbit or anti-mouse, Cell Signaling). Detection of
immunoreactive bands detection was carried out using the
enhanced chemiluminescence (ECL) kit (Amersham) according
to the manufacturer’s instructions.
Dendritic Cell Differentiation From Bone
Marrow Precursors
Dendritic cells (DCs) were obtained from bone marrow of
C57BL/6 and IFNAR1−/− mice as described previously (36).
Briefly, isolated bone marrow cells from femurs and tibiae
were cultured for 7 days at a density of 3 × 106 per 10-
cm dish (10ml) in RPMI medium supplemented with 10%
FBS (PAA Laboratories), 1% v/v glutamine (GlutaMAXTM
100X Gibco), 1% v/v antibiotic (Penicillin 10,000 units/mL–
streptomycin 10,000µg/mL Gibco), 1% v/v of sodium pyruvate
100mM (Gibco) and GM-CSF (10% J558-conditioned medium
v/v), hereafter termed “complete differentiation medium,” in 5%
CO2 and 95% air at 37◦C in a humidified incubator. On day 3,
floating cells were discarded and fresh complete differentiation
medium was added. Cells were further differentiated for an
additional 4 days. Floating and attached cells were separately
examined for their surface marker expressions, and we obtained
attached cells in this study by scraping after gently washing the
culture plates with warm PBS twice. More than 80% of harvested
cells were immature dendritic cells (imDCs) CD11c+.
Transwell Migration Assays
WT or IFNAR−/− CD11c+ imDCs (2 × 105 cells) were
loaded in their own “complete differentiation medium” in the
upper chamber of a Transwell apparatus (5-µm pore size;
Cornings, Lowell, MA), while B16-OVA (TCs) or PDT-treated
B16-OVA (PDT-TCs) (3 × 104 cells) were seeded in the lower
chamber. After 16 h at 37◦C, DCs that have migrated through
the membrane toward the tumor stimuli and attached on the
underside of the membrane were stained with Hoechst dye
for 1 h. After that, epifluorescence images were taken using
an inverted Carl Zeiss fluorescence microscope (UNRC) and
migrating cells were counted in different fields of view (37).
Dendritic Cell Maturation
For dendritic cells maturation analysis, WT or IFNAR−/−
imDCs were co-cultured with B16-OVA (TCs) or with PDT-
treated B16-OVA (PDT-TCs) for 24 h at a 1:1 ratio. As positive
control, imDCs were exposed to LPS (0.5µg/mL) for 24 h. CD86
and MHC-II were used as DC maturation markers evaluated on
the CD11c+ population (36).
Flow Cytometry
Surface staining of single-cell suspensions of dendritic
cells was performed using standard protocols (31) and
analyzed on a Millipore Guava Easycyte 6 2L cytometer.
Data analysis was conducted using FlowJo 10.0.7 software.
The following were obtained from BioLegend: anti-CD11c-
APC (147309), anti-MHC-II-PerCP-Cy5.5 (107626), and
anti-CD86-PeCy5 (105014).
Statistics
Data handling, analysis and graphic representation (all shown
as mean ± SEM) were performed using Prism 7.0 (GraphPad
Software). Statistical data are informed in the corresponding
figure legend.
RESULTS
ER-Associated Cell Death Promoted by
Photodynamic Therapy
By definition, “ICD inducers must be cytotoxic and provoke
cell death above a minimal threshold level” (15). Therefore,
we initially examined the ability of PDT to elicit melanoma
cell death. In this context, B16-OVA were incubated during
4 h with the prodrug Me-ALA to allow the generation of the
photosensitizer PpIX. Upon red-light activation (0.5 J/cm2),
variable cell toxicity dependent on the pro-drug concentration
(0.1–0.35mM) was observed (Figure 1A). No damage was
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induced by the prodrug Me-ALA per se or by red-light
irradiation alone (Figure 1A). As expected, the antioxidant
NAC (30) reversed the cytotoxic effect of high-dose PDT
(Figure 1B). To determine the organelles in which PpIX
was located, we performed co-localization experiments with
mitochondria and endoplasmic reticulum markers. We observed
that PpIX displayed preferential endoplasmic reticulum (ER)
localization (Figure 1C). Pre-incubation of melanoma cells with
the calcium chelator BAPTA-AM (38) inhibited PDT-induced
cell death (Figure 1D), indicative of ER stress associated with
photodynamic effect. The ER response to stress is accompanied
by translocation of danger signals to the cell surface (38). CRT is
the most abundant protein in the ER lumen which translocates
to cell surface in response to stress-mediated dying cells (39).
Here, 72.3% of photosensitized melanoma cells exhibited the
typical “patches” (40) of anterograde intracellular transport of
CRT, suggesting that PDT also modulates CRT mobilization
(Figure 1E).
Enhancement of IFN-1 Expression
Mediated by Photodynamic Treatment
Until now, PDT had been associated with CRT (24, 25), ATP
(26), and HMGB1 (24) exposition and/or release, but there was
no evidence for type I interferon pathway regulation. Having
shown that CRT was translocated through photodynamic stimuli
(Figure 1E) and given the connection between this chaperone
and the modulation of IFN-1 (41), levels of ifn-α/β mRNA
were measured in dying cells undergoing anticancer PDT. B16-
OVA were exposed to Me-ALA (0.1, 0.2, and 0.3mM) and then
irradiated with red light (0.5 J/cm2). Interestingly, a significant
increase in IFN-1 transcription was detected in melanoma
cells as early as 5 h following high-dose photosensitization
(Figure 2A). In addition, as the doses of Me-ALA increased, the
frequency of apoptotic cells (both early and late apoptotic cells)
(Figures 2B,C) and the expression of IFN-α/β also augmented
(Figure 2A), suggesting that an autocrine effect of IFN-1 could be
playing a role in inducing apoptosis. Next, we exposedmelanoma
cells to a lethal dose of PDT (Me-ALA 0.3mM + 0.5 J/cm2) or
doxorubicin (30µM), a relevant chemotherapeutic agent bona
fide ICD inducer (16, 42), analyzing IFN-1 regulation in a time-
course experiment. Notably, PDT was a strong IFNα/β inducer
5 h post-PDT; in contrast the significant upregulation of IFN-
α/β was absent in those subjected to doxorubicin (Figure 2D).
Overall, we provide here experimental data regarding specific in
vitro apoptotic lethal conditions of PDT that strongly induced
IFN-1 in B16-OVA cells.
Photodynamic Autocrine Modulation of
Type 1 Interferon Pathway
Type I IFNs are cytokines of major importance for the innate
antiviral response that have been recently associated to ICD
(16). They are produced after recognition of nucleic acids by
toll-like receptors (TLR3-7-8) or by cytoplasmic proteins, such
as RIG-I like receptors (RIG-1, MDA-5) or the cyclic GMP-
AMP synthase (cGAS), which activate adaptor proteins that
culminate in IRF3 phosphorylation. IRF3 is a transcription factor
that leads the expression of Type 1 interferons. After their
secretion, IFN-α/β bind to their cognate receptor IFNAR1/2,
triggering the phosphorylation of STAT transcription factors,
and the consequent induction of hundreds of interferon-
stimulated genes (ISGs) in the responding cells (7). Based on
our findings (Figure 2), we decided to explore the mechanisms
underlying the photodynamic modulation of IFN-1. After
14 h of PDT-stimulation, an upregulation of cGAS receptor,
but not MDA-5, TLR3, or RIG-1, was detected (Figure 3A).
Interestingly, a significant increase in the transcription of
ISGs CXCL10, ISG15, and MX1 was observed (Figure 3B).
As expected, induction of interferon regulatory factor (IRF)
related genes was paralleled by phosphorylation of IRF3 0.5 h
after photodynamic treatment (Figures 3C,D). The type I IFN
autocrine loop was also manifested in our experimental setting,
since STAT1 phosphorylation was evidenced 1 h after the
initial PpIX photoactivation on tumor cells (Figures 2E,F).
Collectively, these data suggest that Me-ALA-based PDT
stimulates the production of type I IFN and this can act
autocrinally augmenting the transcription of several interferon
stimulated genes.
IFN-1-Dependent Activation of Dendritic
Cells Induced by PDT-Treated Melanoma
Cells
The spatiotemporally coordinated emission of specific DAMPs
promotes the recruitment of DCs to sites of ongoing ICD and
their capacity to prime an adaptive immune response (13).
For this reason, we next examined whether IFN-1 detected in
PDT-melanoma tumor cells (PDT-TCs) could act in a paracrine
fashion on DC migration. Immature WT and IFNAR−/− DCs
were loaded into the upper chamber of transwells with growth
media (Control), B16-OVA (TCs) or photosensitized B16-OVA
(PDT-TCs) in the lower chamber. Although the absence of
IFNAR did not affect the basal migration of dendritic cells
or in response to untreated tumor cells, WT DCs migrated
toward PDT-TCs in much greater numbers than IFNAR−/− DCs
(Figures 4A,B). The expression of cell-surface co-stimulatory
molecules that are involved in DCmaturation, such as CD86 and
MHC-II, was assessed by flow cytometry after 24 h of DCs-TCs
co-culture. Untreated imDCs were used as negative control (DCs
control) and imDCs stimulated by lipopolysaccharide (DCs +
LPS) were used as positive control. Interestingly, PDT-TCs were
capable per se of significantly enhancing the maturation of WT
DCs, which was partially abrogated when IFN-1 receptor was
absent in DCs. Similar results were observed with the positive
control of LPS treatment (Figures 4C–G). Taken together, these
results indicated that apoptotic PDT on melanoma cells induces
the production of type I IFNs, which in turn can promote an
improvement in DC function.
DISCUSSION
The success of cancer treatments fundamentally relies on
the synergic interaction between dying/dead cancer cells and
immune cells. The ideal cancer therapeutic strategy should
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FIGURE 1 | Photodynamic Therapy induced ER-associated cell death and CRT mobilization on melanoma cells. (A) B16-OVA cells were incubated with increasing
concentrations of the pro-drug Me-ALA (0–0.35mM) for 4 h and then were irradiated with visible light (λ: 635 ± 17 nm, light dose: 0.5 J/cm2 ). At 24 h post-treatment,
cell viability was evaluated through the MTT assay and expressed as a percentage with respect to the non-treated control (dotted line: 100% viability). (B) B16-OVA
cells were incubated with Me-ALA (0.1, 0.2, and 0.3mM) in the presence or absence of NAC (5mM) for 4 h and then exposed to irradiation (0.5 J/cm2 ). Viability was
evaluated by MTT assay 24 h post-PDT and referred to non-treated conditions (dotted line: 100% viability). Data are mean ± SEM of three independent experiments.
**p < 0.01 vs. control group (NAC 0mM, gray bars), Two-Way ANOVA Bonferroni post-test. (C) B16-OVA cells transfected with pEYFP-Mito (mitochondrial marker)
and pEYFP-C1-KDEL-GFP (endoplasmic reticulum marker) were incubated for 4 h with the Me-ALA drug (1mM). Next, they were fixed with paraformaldehyde (PAF)
4% for 20min and the cell nuclei were stained with Hoechst (HÖ) for visualization. The fluorescence of PpIX (red), organelles (green), and nuclei (blue) was observed by
confocal microscopy. The co-localization is evidenced in yellow color. The analysis of the images was carried out using the free ImageJ 1.42q software (plugging
Coloc 2) and the correlation was quantified through the Pearson coefficient (r). (D) B16-OVA cells were subjected to high dose PDT (Me-ALA 0.3mM + 0.5 J/cm2 ) in
the presence or absence of BAPTA-AM (1µM) for 4 h. Viability was evaluated by MTT assay 24 h post-PDT and referred to non-treated conditions (dotted line: 100%
viability). Data are mean ± SEM of three independent experiments. *p < 0.05 vs. control group (BAPTA 0µM, gray bars), Two-Way ANOVA Bonferroni post-test.
(E) B16-OVA cells transfected with pCRT-EGFP [green fluorescent protein-tagged calreticulin (CRT)] were subjected to high dose PDT (Me-ALA 0.3mM + 0.5 J/cm2 ).
The fluorescence of CRT (green) was observed by epifluorescence microscopy 0.5 h post-treatment. CRT translocation is marked with a narrow. The analysis of the
images was carried out using the free ImageJ 1.42q software.
involve both direct cytotoxic action on tumor cells and
immunostimulatory effects based on the immune recognition
of molecular antigenic determinants on dying cells. However,
to cause an immune response against malignant cells, the
presence of tumor antigens is not enough. Also, such cells
must emit danger signals, such as danger-associated molecular
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FIGURE 2 | Photodynamic therapy as a novel inductor of IFN-1 expression on melanoma cells. (A) B16-OVA cells were incubated with Me-ALA (0.1, 0.2, and
0.3mM) for 4 h and then were irradiated with visible light (0.5 J/cm2 ). Quantification of mRNA expression of IFN-1α (right) and IFN-β (left) was performed 5 h after
treatment by RTqPCR and normalized with respect to the non-treated control (dotted line: 1). Data are mean ± SEM of three independent experiments. **p < 0.01,
***p < 0.05 vs. control group (untreated cells), One-Way ANOVA Bonferroni post-test. (B) Type of cell death was evaluated using Annexin V/PI staining by flow
cytometry. The data generated by flow cytometry were plotted in two-dimensional dot plots in which PI is represented vs. Annexin V-FICT. (C) Viable cells (Annexin
V−/PI−), undergoing (early) apoptotic cells (Annexin V+/PI−) and dead, necrotic or late (end-stage) apoptotic cells (Annexin V+/PI+) were quantified using FlowJo
10.0.7 software. (D) B16-OVA cells were subjected to high dose PDT (Me-ALA 0.3mM + 0.5 J/cm2 ) or doxorubicin (30µM). Quantification of mRNA expression of
IFN-1-α (right) and IFN-β (left) was performed 1, 5, and 14 h after treatment by RTqPCR and normalized with respect to the non-treated control (dotted line: 1). Data
are mean ± SEM of three independent experiments. **p < 0.01 vs. PDT group (gray bars), Two-Way ANOVA Bonferroni post-test.
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FIGURE 3 | Modulation of IFN-1 pathway by photodynamic therapy. B16-OVA cells were incubated with Me-ALA (0.3mM) for 4 h and then were irradiated with visible
light (λ: 635 ± 17 nm, light dose: 0.5 J/cm2 ) (PDT). Non-treated cells were used as “Control.” (A) Quantification of mRNA expression of receptors MDA-5, TLR3,
RIG-1, and cGAS was performed 14 h after treatment by RTqPCR and normalized with respect to the non-treated control (dotted line: 1). Data are mean ± SEM of
three independent experiments. *p < 0.05 vs. control group (untreated cells, gray bars), Two-Way ANOVA Bonferroni post-test. (B) Quantification of mRNA expression
of ISGs CXCL10, ISG15, and MX1 was performed 14 h after treatment by RTqPCR and normalized with respect to the non-treated control (dotted line: 1). Data are
mean ± SEM of three independent experiments. *p < 0.05, **p < 0.01 vs. control group (untreated cells, gray bars), Two-Way ANOVA Bonferroni post-test.
(C) Western blot was performed to detect phospho-IRF3 at 0.5–6 h post-treatment. The same membrane was stripped and reblotted for α-Tubulin as loading control.
(D) Densitometric analysis performed with the ImageJ software represented the signal intensity of phospho-IRF3; the signal was normalized α-Tubulin intensity.
(E) Western blot was performed to detect phospho-STAT1 at 1–6 h post-treatment. The same membrane was stripped and reblotted for total STAT1 as loading
control. (F) Densitometric analysis performed with the ImageJ software represented the signal intensity of phospho-STAT1; the signal was normalized total STAT1
intensity.
patterns (DAMPs) that work as adjuvants (43). In this context,
several successful antitumor agents have demonstrated to be
highly efficient in stimulating the emission of DAMPs by
cancer cells, thus inducing ICD (15). Two categories have
been proposed in order to classify ICD inducers based on
their direct or indirect ability to cause endoplasmic reticulum
(ER) stress leading to apoptotic cell death. The majority of
ICD inducers, such as chemotherapeutic agents (oxaliplatin
mitoxantrone, doxorubicin, and cyclophosphamide), shikonin,
vorinostat, cardiac glycosides, among others, are categorized as
type I ICD inducers that primarily target cytosolic proteins,
plasma membranes, or nucleic proteins. They also induce ER
stress via collateral effects. On the other hand, type II ICD
inducers, such as hypericin-based PDT and coxsackievirus B3,
preferentially target the ER. The quality and/or quantity of ER
stress induced by ICD, also associated with oxidative stress, may
define the ICD inducer properties, and it was demonstrated
that type II ones are more efficient in terms of immunological
antitumor ability (44).
In the last decades, several investigations have been
devoted on the search of particular stress agents capable
of provoking ICD in cancer cells. Photodynamic therapy
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FIGURE 4 | Phenotypic and functional maturation of dendritic cells mediated by IFN-1 upregulation on PDT-subjected melanoma cells. WT or IFNAR−/− DCs were in
the upper chamber of a Transwell apparatus while B16-OVA (TCs) or with PDT-treated B16-OVA (PDT-TCs) were seeded in the lower chamber. Complete growth
media was used as “control.” (A) After 16 h at 37◦C, DCs that have migrated through the membrane toward the tumor stimuli and attached on the underside of the
membrane were stained with Hoechst dye for 1 h, and epifluorescence images were taken. (B) Migrating cells were counted in different fields of view. Data are mean
± SEM of three independent experiments. *p < 0.05 vs. control group (WT dendritic cells, black bars), Two-Way ANOVA Bonferroni post-test. (C) WT (solid line, gray
filled) or IFNAR−/− DCs (dotted line, non-filled) were co-cultured with B16-OVA (TCs) or with PDT-treated B16-OVA (PDT-TCs) for 24 h in a 1:1 ratio. As positive
control, DCs were exposed to LPS (0.5µg/mL) for 24 h. CD86 and MHC-II were used as DCs maturation markers. Representative flow cytometry histograms were
performed with FlowJo 10.0.7 software. (D) CD86+ cells were referred to untreated imDCs used as negative control (DCs Control, dotted line: 1). Data are mean ±
SEM of three independent experiments. **p < 0.01, ***p < 0.001 vs. control group (WT dendritic cells, black bars), Two-Way ANOVA Bonferroni post-test. (E) CD86
expression intensity of CD86+ cells was indicated by geometric mean (MFI, mean fluorescence intensity) referred to untreated imDCs used as negative control (DCs
Control, dotted line: 1) Data are mean ± SEM of three independent experiments. *p < 0.05 vs. control group (WT dendritic cells, black bars), Two-Way ANOVA
Bonferroni post-test. (F) MHC-II+ cells were referred to untreated imDCs used as negative control (DCs Control, dotted line: 1) Data are mean ± SEM of three
independent experiments. *p < 0.05 vs. control group (WT dendritic cells, black bars), Two-Way ANOVA Bonferroni post-test. (G) MHC-II expression intensity of
MHC-II+ cells was indicated by geometric mean (MFI) referred to untreated imDCs used as negative control (DCs Control, dotted line: 1). Data are mean ± SEM of
three independent experiments. *p < 0.05, ***p < 0.001 vs. control group (WT dendritic cells, black bars), Two-Way ANOVA Bonferroni post-test.
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(PDT), a regulatory approved cancer treatment, has the
ability of inducing immunogenic apoptosis (45, 46). Here,
we demonstrated that oxidative stress induced by PDT
promoted apoptotic cell death (Figures 1, 2B,C). Following
PDT, ROS exhibit a short half-life, thus they exert their effect
close to their site of generation. Consequently, the precise
subcellular localization of the PS within the cell influences
the degree and the type of photodamage. The knowledge
of PS localization is therefore important for choosing the
most effective PS for each purpose (47). For this reason, we
decided to evaluate the precise location of PpIX. Under our
experimental conditions, PpIX localized in ER (Figure 1C),
suggesting this organelle as its major target. In addition, ER-
stress was associated with photodynamic effect (Figure 1D).
These data postulated Me-ALA based-PDT as a potential Type-II
ICD inducer.
ICD is a death mechanism in which specific stimuli lethally
damage cancer cells while producing the spatiotemporally
emission of immunogenic signals (15). Previous reports
demonstrated the photodynamic mobilization of some
of the main DAMPs involved in ICD, such as ATP (26),
HMGB1 (24), and CRT (24, 25). In this sense, in the current
work, we observed a significant translocation of CRT from
ER to plasma membrane (Figure 2E). In an ICD context,
this translocation of CRT occurs in a pre-apoptotic stage
(before translocation of phosphatidylserine to the outer side
of the plasma membrane) (39, 40). The ecto-CRT serves
as a potent “eat me” signal for local patrolling DCs (39).
For immunogenicity to be detected, dying cells must emit
signals in addition to CRT. In fact, recently the capacity
of surface-exposed CRT to initiate type I IFN-dependent
anticancer immunity was shown (41). The immune response
against cancer generated by type-I-interferons (IFN-1) has
recently described. Exogenous and endogenous IFN-α/β have
an important role in immune surveillance and control of
tumor development. Accordingly, the role of TLR agonists as
cancer therapeutic agents is being revisited with the idea of
stimulating the production of endogenous type I IFN inside the
tumor (31, 34, 36).
In addition, type-I-interferons (IFN-1) have recently emerged
as novel DAMPs for the sequential events bridging innate
and cognate immunity (16, 48). Both IFN-1 as well as
ISGs had been activated in vitro and in vivo following
anthracycline-based chemotherapy. It was described how the
cancer autocrine axis of TLR3 > IFNs-I > IFNAR affects
immunogenicity of anthracycline-mediated tumor cell death
(14, 16). Based on these findings, IFN-1s are now classified as
a Class IIIA DAMPs: endogenous native molecules operating
as inducible DAMPs (49). Interestingly, to the best of our
knowledge, the present study is the first to report the
in vitro upregulation of IFN-1 expression in response to
photodynamic treatment in melanoma (Figure 2). Our data
suggest that Me-ALA based PDT stimulate the production
of IFN-α/β and related ISGs through an autocrine molecular
pathway (Figure 3).
For a successful immunogenic cell death promotion, the
concomitant DAMPs must have activating effects on dendritic
cells (DCs). DCs are mobile cells, and this feature is crucial
for their antitumor action in vivo for the proper detection
and capture of tumor antigens in peripheral tissues. Next,
DCs upregulate the expression of co-stimulatory molecules,
in order to cross-present and activate antigen-specific T
cells. DAMPs recognition is an essential requirement for the
activation of immature DCs associated with the expression of
co-stimulatory T cell molecules (50). Here, we demonstrated
that photosensitized melanoma promotion of both DCs
migration to tumor site and DCs maturation was dependent
on IFN-1 signaling (Figure 4). Taken together, our results
show that cancer cells subjected to oxidative stress due to
ER-associated pro-apoptotic PDT could potentiate antitumor
immunity through an autocrine/paracrine activation of
IFN-1 pathway.
In recent years, anticancer vaccination success has been
correlated with the immunogenic potential of dead/dying cells
used as antigen/adjuvant source. The danger signals-dependent
efficacy of ICD-based DC vaccines has recently been shown
(17, 51–54). However, chemical ICD inducers are not desirable
for production of DC-based vaccines because they either leave
residual drug concentrations behind or may exert cytotoxicity
against DCs. For that reason, appropriate preselection of ICD
should be critically considered (55–57). In this sense, as the
prodrug Me-ALA is not toxic per se (Figure 1A), and given the
immune stimulation properties observed (Figure 4), the PDT
conditions here tested could represent a promising approach in
the design of ICD-based DCs vaccines.
Collectively, our findings showed the effects of a novel
danger signal released by PDT-treated cancer cells on the
activation of DCs, emphasizing the potential relevance of PDT
in adoptive/personalized immunotherapy protocols.
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